Selected research
Industry Research
Softgel CDMO Industry Research Report 2026
Market perspective
The global Softgel CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Softgel CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Softgel CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Softgel CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Softgel CDMO include Procaps, Patheon, NextPharma, Lonza, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Softgel CDMO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Softgel CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Softgel CDMO Market by Company
Procaps
Patheon
NextPharma
Lonza
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
Catalent
Aenova
Sirio Pharma
Softgel CDMO Segment by Type
Pharmaceutical Softgel CDMO
Nutraceutical Softgel CDMO
Others
Softgel CDMO Segment by Application
Pharmaceutical Company
Biotechnology Company
Others
Softgel CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Softgel CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Softgel CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Softgel CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Softgel CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pharmaceutical Softgel CDMO
- Nutraceutical Softgel CDMO
- Others
Applications
- Pharmaceutical Company
- Biotechnology Company
- Others
Companies covered
- Procaps
- Patheon
- NextPharma
- Lonza
- Samsung Biologics
- Fareva
- WuXi AppTech
- WuXi Biologics
- Siegfried
- Catalent
- Aenova
- Sirio Pharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Softgel CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Pharmaceutical Softgel CDMO
- 2.2.3 Nutraceutical Softgel CDMO
- 2.2.4 Others
- 2.3 Softgel CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Company
- 2.3.3 Biotechnology Company
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Softgel CDMO Breakdown Data by Type
- 3.1 Global Softgel CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Softgel CDMO Forecasted Market Size by Type (2027-2032)
4 Softgel CDMO Breakdown Data by Application
- 4.1 Global Softgel CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Softgel CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Softgel CDMO Market Perspective (2021-2032)
- 5.2 Global Softgel CDMO Growth Trends by Region
- 5.2.1 Global Softgel CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Softgel CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Softgel CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Softgel CDMO Market Dynamics
- 5.3.1 Softgel CDMO Industry Trends
- 5.3.2 Softgel CDMO Market Drivers
- 5.3.3 Softgel CDMO Market Challenges
- 5.3.4 Softgel CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Softgel CDMO Players by Revenue
- 6.1.1 Global Top Softgel CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Softgel CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Softgel CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Softgel CDMO Head Office and Area Served
- 6.4 Global Softgel CDMO Players, Product Type & Application
- 6.5 Global Softgel CDMO Manufacturers Established Date
- 6.6 Global Softgel CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Softgel CDMO Market Size (2021-2032)
- 7.2 North America Softgel CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Softgel CDMO Market Size by Country (2021-2026)
- 7.4 North America Softgel CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Softgel CDMO Market Size (2021-2032)
- 8.2 Europe Softgel CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Softgel CDMO Market Size by Country (2021-2026)
- 8.4 Europe Softgel CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Softgel CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Softgel CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Softgel CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Softgel CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Softgel CDMO Market Size (2021-2032)
- 10.2 South America Softgel CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Softgel CDMO Market Size by Country (2021-2026)
- 10.4 South America Softgel CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Softgel CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Softgel CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Softgel CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Softgel CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Procaps
- 12.1.1 Procaps Company Information
- 12.1.2 Procaps Business Overview
- 12.1.3 Procaps Revenue in Softgel CDMO Business (2021-2026)
- 12.1.4 Procaps Softgel CDMO Product Portfolio
- 12.1.5 Procaps Recent Developments
- 12.2 Patheon
- 12.2.1 Patheon Company Information
- 12.2.2 Patheon Business Overview
- 12.2.3 Patheon Revenue in Softgel CDMO Business (2021-2026)
- 12.2.4 Patheon Softgel CDMO Product Portfolio
- 12.2.5 Patheon Recent Developments
- 12.3 NextPharma
- 12.3.1 NextPharma Company Information
- 12.3.2 NextPharma Business Overview
- 12.3.3 NextPharma Revenue in Softgel CDMO Business (2021-2026)
- 12.3.4 NextPharma Softgel CDMO Product Portfolio
- 12.3.5 NextPharma Recent Developments
- 12.4 Lonza
- 12.4.1 Lonza Company Information
- 12.4.2 Lonza Business Overview
- 12.4.3 Lonza Revenue in Softgel CDMO Business (2021-2026)
- 12.4.4 Lonza Softgel CDMO Product Portfolio
- 12.4.5 Lonza Recent Developments
- 12.5 Samsung Biologics
- 12.5.1 Samsung Biologics Company Information
- 12.5.2 Samsung Biologics Business Overview
- 12.5.3 Samsung Biologics Revenue in Softgel CDMO Business (2021-2026)
- 12.5.4 Samsung Biologics Softgel CDMO Product Portfolio
- 12.5.5 Samsung Biologics Recent Developments
- 12.6 Fareva
- 12.6.1 Fareva Company Information
- 12.6.2 Fareva Business Overview
- 12.6.3 Fareva Revenue in Softgel CDMO Business (2021-2026)
- 12.6.4 Fareva Softgel CDMO Product Portfolio
- 12.6.5 Fareva Recent Developments
- 12.7 WuXi AppTech
- 12.7.1 WuXi AppTech Company Information
- 12.7.2 WuXi AppTech Business Overview
- 12.7.3 WuXi AppTech Revenue in Softgel CDMO Business (2021-2026)
- 12.7.4 WuXi AppTech Softgel CDMO Product Portfolio
- 12.7.5 WuXi AppTech Recent Developments
- 12.8 WuXi Biologics
- 12.8.1 WuXi Biologics Company Information
- 12.8.2 WuXi Biologics Business Overview
- 12.8.3 WuXi Biologics Revenue in Softgel CDMO Business (2021-2026)
- 12.8.4 WuXi Biologics Softgel CDMO Product Portfolio
- 12.8.5 WuXi Biologics Recent Developments
- 12.9 Siegfried
- 12.9.1 Siegfried Company Information
- 12.9.2 Siegfried Business Overview
- 12.9.3 Siegfried Revenue in Softgel CDMO Business (2021-2026)
- 12.9.4 Siegfried Softgel CDMO Product Portfolio
- 12.9.5 Siegfried Recent Developments
- 12.10 Catalent
- 12.10.1 Catalent Company Information
- 12.10.2 Catalent Business Overview
- 12.10.3 Catalent Revenue in Softgel CDMO Business (2021-2026)
- 12.10.4 Catalent Softgel CDMO Product Portfolio
- 12.10.5 Catalent Recent Developments
- 12.11 Aenova
- 12.11.1 Aenova Company Information
- 12.11.2 Aenova Business Overview
- 12.11.3 Aenova Revenue in Softgel CDMO Business (2021-2026)
- 12.11.4 Aenova Softgel CDMO Product Portfolio
- 12.11.5 Aenova Recent Developments
- 12.12 Sirio Pharma
- 12.12.1 Sirio Pharma Company Information
- 12.12.2 Sirio Pharma Business Overview
- 12.12.3 Sirio Pharma Revenue in Softgel CDMO Business (2021-2026)
- 12.12.4 Sirio Pharma Softgel CDMO Product Portfolio
- 12.12.5 Sirio Pharma Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst